Medicine for treating osteoporosis caused by liver-kidney yin deficiency and preparation method of medicine

Abstract

The invention discloses a medicine for treating osteoporosis caused by liver-kidney yin deficiency and a preparation method of the medicine. The medicine comprises the following medicinal materials: purpleflower holly fruits, pork liver, lamb liver, deer horn, wolfberry fruit, clove, teasel root, radix achyranthis bidentatae, fructus amomi, flatstem milkvetch seed, mulberry, spina date seed, korean pine seed, walnut kernel, codonopsis convolvulacea, lucid ganoderma, bamboo juice, human placenta, bloody clam, rhizoma cibotii, sugarcane, astilbe chinensis, parabarium micranthum pierre, pyrola, divaricate saposhnikovia root, oat grass, unpleasant swallowwort herb, cowpea, tendrilleaf solomonseal rhizome, herminium monorchis and turtle meat. The medicine has the efficacies of tonifying the liver, benefiting the kidneys, benefiting qi, nourishing blood, strengthening tendons and bones, tonifying qi, strengthening exterior, nourishing yin and nourishing the kidneys, and is mainly used for treating osteoporosis caused by liver-kidney yin deficiency. The medicine is based on the theory of the traditional Chinese medicine, emphasizes the holistic view is stressed and has the function of relieving the problem of bones by adjusting the whole body; and the medicine is capable of restoring bone health, relieving pain, and improving the symptoms of osteoporosis, and is safe, effective, convenient to take, good in treatment effect, fast in acting, low in recurring rate and free of side effects.

Description

technical field [0001] The invention relates to a medical preparation containing raw materials derived from plants, animals or minerals, in particular to a medicine for treating liver and kidney yin deficiency type osteoporosis and a preparation method thereof. Background technique [0002] Osteoporosis is a systemic bone metabolic disease characterized by low bone mass and microarchitectural destruction of bone tissue, resulting in increased bone fragility and susceptibility to fracture. The disease is common in the elderly, but it can occur at any age. Osteoporosis can be divided into primary and secondary types. Primary osteoporosis refers to other diseases that do not cause the disease; secondary osteoporosis refers to the reduction of bone tissue due to various systemic or endocrine and metabolic diseases. In addition, according to the site of occurrence, it can also be divided into localized or generalized osteoporosis. [0003] Symptoms and signs: Osteoporosis wi...

AI Technical Summary

Problems solved by technology

(3) Calcitonin (CT) deficiency: after menopause, the level of CT decreases, which may contribute to the occurrence of osteoporosis due to the weakening of factors that inhibit bone resorption

(4) The role of other hormones: some data show that patients with primary osteoporosis have abnormal secretion of thyroid hormones, glucocorticoids, growth hormones, life factors (especially growth interferon C), and gastrin, but their Etiological significance not clarified

2. The treatment of specific etiology should not be ignored, especially the overlapping existence of primary osteoporosis and secondary osteoporosis should not be ignored

6. It is not advisable to combine two or more bone resorption inhibitors. Bone resorption inhibitors include estrogen, estrogen receptor modulators, bisphosphonates, and calcitonin. One or more, and when applied in sufficient amount (for example: while adequate dose of female hormone replacement, application of alendronate sodium (Fosamax) 10 mg per day), although the increase of bone density is more effective, it is not yet known The impact on "bone microstructure", "bone fragility" and "fracture incidence"